Market Newsdesk

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — CCL Industries Inc. (TSX:CCL.A) (TSX:CCL.B), a world leader in specialty label, security and packaging solutions for global corporations, government institutions, small businesses and consumers, announced today the closing of the acquisition of Super Enterprises Printing (Malaysia) Sdn. Bhd. (“SEP”), based in Kuala Lumpur, Malaysia. The company now trades as “CCL Design” with immediate effect.

Forward-looking Statements

This press release contains forward-looking information and forward-looking statements, as defined under applicable securities laws, (hereinafter collectively referred to as “forward-looking statements”) that involve a number of risks and uncertainties. Forward-looking statements include all statements that are predictive in nature or depend on future events or conditions. Forward looking statements are typically identified by the words “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions. Statements regarding the operations, business, financial condition, priorities, ongoing objectives, strategies and outlook of the Company, other than statements of historical fact, are forward-looking statements.  

Forward-looking statements are not guarantees of future performance. They involve known and unknown risks and uncertainties relating to future events and conditions including, but not limited to, the impact  of the outbreak of the novel coronavirus known as COVID-19; instability of the world economy and capital markets; the impact of competition; consumer confidence and spending preferences; general economic and geopolitical conditions; currency exchange rates; interest rates and credit availability; technological changes; changes in government regulations; risks associated with operating and product hazards; and the Company’s ability to attract and retain qualified employees. Do not unduly rely on forward-looking statements as the Company’s actual results could differ materially from those anticipated in these forward-looking statements.

Forward-looking statements are also based on a number of assumptions, which may prove to be incorrect, including, but not limited to, assumptions about the following: consumer spending; improved customer demand for the Company’s products; continued historical growth trends, market growth in specific sectors and entering into new markets; the Company’s ability to provide a wide range of products to multinational customers on a global basis; the benefits of the Company’s focused strategies and operational approach; the achievement of the Company’s plans for improved efficiency and lower costs, including stable aluminum and resin costs; the availability of cash and credit; fluctuations of currency exchange rates and the Company’s continued relations with its customers. Should one or more risks come to fruition or should any assumption prove incorrect, then actual results could vary materially from those expressed or implied in the forward looking statements. Further details on key risks can be found in Section 4: “Risks and Uncertainties” of the 2019 Annual MD&A and and CCL’s Interim quarterly report for the period ended September 30, 2020.

For more information on CCL, visit – www.cclind.com or contact:

Sean Washchuk	Senior Vice President	416-756-8526
	and Chief Financial Officer

CCL Industries Inc. employs approximately 21,700 people operating 188 production facilities in 42 countries with corporate offices in Toronto, Canada, and Framingham, Massachusetts. CCL is the world’s largest converter of pressure sensitive and specialty extruded film materials for a wide range of decorative, instructional, functional and security applications for government institutions and large global customers in the consumer packaging, healthcare & chemicals, consumer electronic device and automotive markets. Extruded & laminated plastic tubes, aluminum aerosols & specialty bottles, folded instructional leaflets, precision decorated & die cut components, electronic displays, polymer banknote substrate and other complementary products and services are sold in parallel to specific end-use markets. Avery is the world’s largest supplier of labels, specialty converted media and software solutions for short-run digital printing applications for businesses and consumers available alongside complementary products sold through distributors, mass market stores and e-commerce retailers. Checkpoint is a leading developer of RF and RFID based technology systems for loss prevention and inventory management applications, including labeling and tagging solutions, for the retail and apparel industries worldwide. Innovia is a leading global producer of specialty, high performance, multi-layer, surface engineered films for label, packaging and security applications. The Company is partly backward integrated into materials science with capabilities in polymer extrusion, adhesive development, coating & lamination, surface engineering and metallurgy; deployed as needed across the four business segments.

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) — RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt:IJA2) (the “Company”) is pleased to announce that it has today incorporated into RevoluSEND sixty-eight extra countries and territories. Leveraging the PSD2 banking license and passporting approval, RevoluSEND now permits instant in-app remittance and bank transfers to an impressive group of additional countries.

SEPA
& IBAN
Added to
RevoluSEND

Further to the news release dated 24^th November 2020, the Company has completed the integration of 68 additional countries and territories into the RevoluSEND remittance vertical ahead of schedule. RevoluPAY app users may now send via RevoluSEND instant in-app transfers to proprietary or third-party bank accounts in: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Great Britain, Greece, Greenland, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Albania, Azerbaijan, East Timor, El Salvador, Georgia, Israel, Kazakhstan, Kosovo, Kuwait, Macedonia, Montenegro, Palestine, São Tomé & Príncipe, Saudi Arabia, Andorra, Bahrain, Belarus, Bosnia & Herzegovina, British Virgin Islands, Cyprus, Gibraltar, Iraq, Jordan, Lebanon, Luxembourg, Malta, Rep. Mauritius, Mauritius Islands, Moldova, Monaco, Pakistan, Qatar, Saint Lucia, San Marino, Serbia, Seychelles, Switzerland, Turkey, Tunisia, Ukraine, United Arab Emirates.

Additional
Direct Passporting Countries

Additional to BTS and Thunes, the Company has also reached an autonomous interbank passporting functionality enabling bank transfers from RevoluPAY via RevoluSEND to Brazil, Costa Rica, Dominican Republic, Faroe Islands, and Guatemala. Since passporting countries are directly processed, no third-party delivery commissions are payable.

Open Banking Path Emerging

The Neobanking functionality of RevoluPAY is evolving into a one-stop banking app to challenge conventional bank accounts with proprietary mobile app-based technology. Today’s step enables users to instantly transmit payments from RevoluPAY to an impressive swathe of countries expected to exceed 130 in total by year’s end. As proved, RevoluSEND realizes such transactions at a fraction of the cost imposed by conventional banks or remittance entities. Future projected enhancements focus upon multicurrency, supporting in-app on-the-fly switchable currency accounts initially in CA$, USD, Euro, and GBP. Enabling RevoluPAY users to deposit a specific currency and transact directly in that currency is the next short-term corporate goal.

Exercise of I
ncentive
S
hare
O
ptions

CEO Steve Marshall has exercised an initial tranche of 500,000 of the incentive share options announced on 26^th June 2020 for a total of 120,000 $CA.

Links Used in This News Release

RevoluSEND https://revolusend.com/
RevoluPAY Passporting https://shortly.cc/2AbXI
PSD2 License https://shortly.cc/KAaNM
Ukraine Remittances https://shortly.cc/odfxA
Romania Remittances https://shortly.cc/3nVNA
Poland Remittances https://shortly.cc/Oo0OA
Serbia Remittances https://shortly.cc/cPOw0
European Remittance Study https://shortly.cc/8tGgT

A
bout RevoluPAY®

The Company’s flagship technology is RevoluPAY®, the Apple and Android multinational payment app. Built entirely in-house, RevoluPAY features proprietary, sector-specific technology of which the resulting source code is the property of the Company. RevoluPAY built-in features include Remittance Payments, Retail and Hospitality payments, Real Estate Payments, pay-as-you-go phone top-ups, Gift Cards & Online Credits, Utility Bill payments, Leisure payments, Travel Payments, etc. RevoluPAY is powered by blockchain protocols and is squarely aimed at the worldwide multi-billion dollar leisure sector and, + $595 billion family remittance market. RevoluPAY® is operated by the European wholly-owned subsidiary RevoluPAY S.L located in Barcelona. RevoluPAY S.L is the self-licensed European PSD2 payment institution 6900 under the auspices of E.U. Directive 2015/2366 and EU Passporting. RevoluGROUP Canada Inc. controls five wholly-owned subsidiaries on four continents.

About
RevoluGROUP Canada Inc.
:

RevoluGROUP Canada Inc. is a multi-asset, multidivisional publicly traded Canadian Company deploying advanced technologies in the; Banking, Mobile Apps, Money Remittance, Mobile Phone Top-Ups, EGaming, Healthcare Payments, Esports, Invoice factoring, Online Travel, Vacation Resort, Blockchain Systems, and Fintech app sectors. Click here to read more.

For further information on RevoluGROUP Canada Inc. (TSX-V: REVO), visit the Company’s website at www.RevoluGROUP.com. The Company has approximately 166,414,015 shares issued and outstanding.

RevoluGROUP Canada
,
Inc.

“
Steve Marshall
“

______________________
STEVE MARSHALL
CEO

For further information, contact:
RevoluGROUP Canada Inc.
Telephone: (604) 332 5355
Facsimile: (604) 687 3119
Email: [email protected]

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This release includes certain statements that may be deemed to be “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedar.com for further information.

PHILADELPHIA, Nov. 30, 2020 (GLOBE NEWSWIRE) — Scout Bio, a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions, today announced that Mark Heffernan, Scout Bio’s Chief Executive Officer, will present on the “Blockbusters of 2024” panel at the upcoming Guggenheim Healthcare Talks Animal Health Veterinary Summit at 1:20 p.m. ET on Monday, December 7, 2020.

About Scout Bio

Scout Bio is a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions. Scout has an exclusive research and development collaboration with the University of Pennsylvania’s Gene Therapy Program, which has been a global leader in gene therapy research and development for nearly three decades. Scout’s therapeutics are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Scout Bio is ​a private company headquartered in Philadelphia, PA. For more information, please visit www.scoutbio.co.

Investor Contact:

Sarah McCabe
Stern Investor Relations, Inc.
212.362.1200
[email protected]

Media:
Fran Gaconnier
Scout Bio
214.417.4142
[email protected]

NASHUA, N.H., Nov. 30, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company is showcasing its leading Breast Health Solutions, including the expanded ProFound AI^® platform powered by Panorama, at the 106^th Scientific Assembly and virtual Annual Meeting of the Radiological Society of North America (RSNA), November 29 – December 5.

The Company’s full suite of solutions includes the latest generation of ProFound AI for Digital Breast Tomosynthesis (DBT), the first artificial intelligence (AI) cancer detection software for DBT to be cleared by the US Food & Drug Administration, as well as ProFound AI for 2D Mammography,* and ProFound AI Risk for 2D mammography, the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation based solely on a screening mammogram.

“Our efforts to commercialize pioneering solutions positioned to enhance patient care and improve outcomes is underscored by the superior performance and unrivaled specificity of our breast imaging AI that is transforming breast cancer detection and risk-based, personalized screening,” said Michael Klein, Chairman and CEO of iCAD. “We’re thrilled to highlight our expanded ProFound AI platform powered by Panorama at RSNA 2020, which is poised to further boost radiologists’ performance, improve detection and care, and is uniquely positioned to address the ongoing challenges presented by COVID-19.”

“Our new ProFound AI Risk is helping to change the way breast cancer risk is assessed and contribute to the acceleration of breast cancer screening from an aged-based screening paradigm to a risk-adapted screening paradigm,” continued Klein. “It is extremely gratifying to fulfill our panoramic vision of providing a complete clinical approach with a broader view of each patient’s case, history, and short-term risk, for truly personalized and enhanced patient care.”

ProFound AI Risk was created from a relationship between iCAD and leading researchers at the Karolinska Institutet in Stockholm, Sweden. This partnership is built upon a previous research agreement whereby researchers at the Karolinska Institutet developed a breast cancer risk prediction model using information identified in mammography images provided by iCAD’s AI solutions. The clinical decision support tool combines aspects within mammographic images, as well as age and breast density, to provide a highly accurate short-term risk estimation that is specific to each woman.

“The Profound AI Risk model performs better than any other current model,” according to Per Hall, MD, Professor/Senior Physician at the Karolinska Institutet. “The model is a short-term risk model which is an advantage in the screening setting, builds heavily on analyses of mammograms, is easy and inexpensive to implement and has little requirement of staff and systems to manage the data. Further, the risk model was also tested using other variables, such as lifestyle factors and genetic determinants, which may be added to the iCAD product in the future.”

Compelling research published in the peer-reviewed journal, Radiology, reveals that ProFound AI Risk significantly outperforms existing breast cancer risk models.

Trained with one of the largest available DBT datasets, ProFound AI rapidly and accurately analyzes each DBT image, or slice, and provides radiologists with key information, such as Certainty of Finding lesion and Case Scores, which assists in clinical decision-making and improving reading efficiency. Featuring the latest in deep-learning artificial intelligence, the algorithm allows for continuously improved performance in detection via ongoing updates. ProFound AI for DBT and 2D mammography* is compatible with a majority of leading DBT and digital 2D mammography systems.

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

ProFound AI for DBT is proven to curtail workflow challenges substantially by reducing radiologists’ reading time by 52.7 percent, thereby reducing by half the amount of time it takes radiologists to read 3D mammography datasets. Additionally, the platform improved radiologists’ sensitivity by 8 percent and reduced unnecessary patient recall rates by 7 percent.ⁱ

ProFound AI Risk is currently available on an introductory basis for 2D mammography and will subsequently be available for the rapidly growing 3D mammography market.

For more information, visit www.icadmed.com and www.xoftinc.com

Forward-Looking Statements

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

*CE Mark countries only.

Media Inquiries:

Amy Cook, iCAD
+1 (925) 200-2125
[email protected]

Investor Relations:

Jeremy Feffer, LifeSci Advisors
+1 (212) 915-2568
[email protected]

---

ⁱ Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096

Review
p
ositive
i
nterim
d
ata
from
the
study
of
i
tolizumab
for the treatment of
a
cute GVHD
and
p
ipeline
p
rograms in
lupus /
l
upus
n
ephritis and
uncontrolled
a
sthma

Featur
ed
g
uest
s
peaker:
John Koreth, M
.
D
.
, D
.
Phil
.
of Dana-Farber Cancer Institute

LA JOLLA, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it will host a virtual Investor and Analyst Day on December 4, 2020, from 9:30 a.m. to 12:00 p.m. ET. The event will include a review of the company’s lead clinical drug candidate, itolizumab, a first-in-class monoclonal antibody, which is being investigated in ongoing trials in acute graft-versus-host disease (aGVHD), lupus / lupus nephritis and uncontrolled asthma.

Presenters include:

•	John Koreth, M.D., D.Phil. of Dana-Farber Cancer Institute
	○	Providing a physician’s perspective on itolizumab in GVHD
•	Bruce Steel, Chief Executive Officer
•	Steve Connelly, Ph.D., Chief Scientific Officer
•	Krishna Polu, M.D., Chief Medical Officer
•	Joel Rothman, SVP Development Operations
•	Jason Keyes, Chief Financial Officer

The presentations will be followed by Q&A with management and Dr. Koreth.

A live webcast of the event will be available for 30 days on the Events & Presentations page of the Investor Relations section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations.

About Itolizumab

Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including aGVHD, lupus / lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential benefit of treating patients with aGVHD, lupus / lupus nephritis or uncontrolled asthma with itolizumab, Equillium’s business strategy, Equillium’s plans and expected timing for developing itolizumab, including the expected timing of initiating, completing and announcing further results from the EQUATE, EQUIP and EQUALISE studies, the potential benefits of itolizumab, the potential for any of Equillium’s ongoing or planned clinical trials to show safety or efficacy, and the impact of the COVID-19 pandemic. Risks that contribute to the uncertain nature of the forward-looking statements include: the risk that interim results of a clinical trial do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that studies will not be completed as planned; uncertainties related to Equillium’s capital requirements; Equillium’s plans and product development, including the initiation, restarting and completion of clinical trials; uncertainties related to the actual impacts and length of such impacts caused by the COVID-19 pandemic; uncertainties caused by the recent restarting of the EQUIP and EQUALISE clinical trials after a pause; whether the results from clinical trials will validate and support the safety and efficacy of itolizumab; changes in the competitive landscape, and uncertainties having to use cash in ways or on timing other than expected and the impact of market volatility on cash reserves. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in Equillium’s filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact

Michael Moore,
Vice President, Investor Relations & Corporate Communications
+1-619-302-4431
[email protected]

Media Contact

Katherine Carlyle Smith
Senior Account Associate
Canale Communications
+1-805-907-2497
[email protected]

CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it has created a new Pain Care Division focused on the rapidly growing segment of pain care.

Pain management has become more prevalent in recent years as neuro spine and ortho spine surgeons have changed the way they manage patients suffering from chronic back pain issues. Many practices now offer pain management and employ more pain interventionalists than spine surgeons, as there are newer products and services to help treat patients, including Aurora’s ZIP™ and SiLO™. In addition, many pain management physicians are seeking to reduce the use of opioids and increasingly using mechanical devices such as the ZIP™ and SiLO™.

The ZIP™ Screwless Fusion Procedure for the treatment of back pain is a series of patented implants developed by Aurora Spine specifically for the L5-S1 region, including Aurora Spine’s minimally invasive interspinous fixation implant designed for stabilization and load sharing in T1-S1 thoracolumbar fusion procedures.

SiLO™ is a single implant Posterior Si-Fusion System and was developed to provide a simple, safe & reproducible method of fusing the Sacroiliac Joint. SiLO™ is the only implant that was designed specifically for posterior sacroiliac joint fusions. The implant design consists of three levels of ridges along its circumferential solid body to increase implant retention and solidity through its unique “Dowel Anchorage Design”. The SiLO implant is shaped for enhanced 360-degree bone incorporation along with dual, vertical side channels.

“We are excited to announce the launch of our new Aurora Spine Pain Care division. The pain management market has experienced sizable growth in recent years and is expected to continue to grow for the foreseeable future,” said Trent Northcutt, President and CEO of Aurora Spine. “The pain care market has been a rapidly growing sector of the spinal health market. Many practices have established pain care within their practices to implement new treatments to treat back pain before sending a patient to surgery. Seeing these shifts in the market, Aurora created new products for the pain care marketplace, including products that can assist pain interventionists when treating patients and avoid or limit the use of opioids. We believe our focus on the pain care market will allow us to leverage several Aurora products into the pain care marketplace and offer patients and doctors more solutions to helping them treat chronic back pain.”

Dr. Vipul Mangal, Director of Implantable Systems at National Spine & Pain Centers in National Harbor, Maryland, stated, “Aurora Pain Care offers modern, minimally invasive treatment of back pain for my patients. Performing these cases at an outpatient surgery center is the future of minimally invasive spine surgery. I find that the device is easy to implant, and patients have had significant functional improvement in mobility and activities of daily living along with decrease in their pain.”

The global pain management devices market size is expected to reach USD $14.55 billion by 2026 registering a CAGR of 13.8%. For additional information about Aurora Spine’s Pain Care Division, go to: www.aurorapaincare.com.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s final prospectus (collectively, “forward-looking information”). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine’s securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Contact:

Aurora Spine Corporation

Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com

Adam Lowensteiner
LYTHAM PARTNERS, LLC
Phoenix | New York
Telephone: 646-829-9700
[email protected]

WESTLAKE VILLAGE, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — MannKind Corporation (NASDAQ:MNKD) today announced that Sabrina Kay Ed.D. has been appointed to its Board of Directors, effective December 1, 2020. Dr.  Kay will also serve as a member of the Audit Committee of the Board. A serial entrepreneur, tech educator, fashion designer, philanthropist, and public speaker, Dr. Kay brings to MannKind a wealth of experience in marketing, human capital development, finance and executive leadership.

“We are excited to welcome Dr. Kay and her years of invaluable leadership to our Board of Directors,” said Kent Kresa, Chairman of the Board. “Her entrepreneurial vision will be a critical asset for MannKind as the company continues to evolve and the pipeline expands. Dr. Kay has a successful track record in launching and leading a variety of companies, and will add a fresh and diverse perspective as we continue to pursue our mission to give people control of their health and the freedom to live life.” 

Currently, Dr. Kay serves as Founder and CEO of Fremont Private Investments, where she has led the operations and exits of several companies including The Art Institute of Hollywood (sold to NASDAQ: EDMC), Premier Business Bank (sold to NASDAQ: FFWM), Fashion Umbrella, Fremont College, and Dale Carnegie of Los Angeles.

In addition to her success in the business world, Dr. Kay is a philanthropist, having served on more than 30 charitable and civic boards. She is chairman of After-School All-Stars Los Angeles, and a board member of the Los Angeles Sports and Entertainment Commission, Petersen Automotive Museum, Portal Schools, the Leadership Council of International Medical Corps Leadership Council, and the Board of Leaders of USC Marshall School. Dr. Kay has also chaired and spoken at numerous tech, education, business, and leadership conferences, and taught entrepreneurship programs at various universities.

Dr. Kay’s achievements have been recognized with numerous awards, including the Education Award from After-School All-Stars and the Humanitarian Award from International Medical Corps. She was named Woman of the Year by the California Legislature, Rising Asian Woman by the World Affairs Council, and was a finalist for Entrepreneur of the Year by Ernst & Young.

Dr. Kay received her joint doctorate degree in Work-based Learning Leadership from the University of Pennsylvania. She holds an MBA from the University of Southern California and a Master of Science degree in education from the University of Pennsylvania.

With the addition of Dr. Kay, there are nine members of the MannKind Board of Directors.

About MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind’s filings with the SEC. For a discussion of these and other factors, please refer to MannKind’s annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind’s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Company Contact:

818-661-5000
[email protected]

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or “the Company”) (TSX:FM) today announced the filing of an updated National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) Technical Report dated November, 2020 for the Taca Taca development project (the “Report”). Taca Taca is a copper, molybdenum and gold project located in the Puna (Altiplano) region of Salta Province, in northwest Argentina. The Report documents an updated Mineral Resource model and a significant maiden Mineral Reserve estimate derived from an open pit mine design and plan which contemplates processing throughput of up to 60 million tonnes per annum through a conventional flotation circuit with a mine life of approximately 32 years. The recovered copper reaches a peak of approximately 275,000 tonnes within the first ten years of operations. The design is based on the process plants which the Company has successfully constructed and operated at its Sentinel and Cobre Panama operations.

A decision to proceed with the construction of Taca Taca is not expected until sometime in 2023 or 2024. The Company remains focused on deleveraging its balance sheet over this period. Work will continue to advance the project and to further refine and optimize the plan while obtaining the required approvals and permits and suitable assurances with respect to the Argentinian fiscal regime in advance of a formal construction decision.

The updated Measured and Indicated Mineral Resource is 2,203.3 million tonnes of grading 0.43% copper for 9,450.7 kt of contained copper, 264.5 kt of molybdenum and 6,052.1 koz of gold. The Proven and Probable Mineral Reserve has been estimated at 1,758.5 Mt of ore grading 0.44% copper for 7,734.7 of contained copper, 213.5 kt of Mo and 5,086.7 koz of Au. (See Table 1 and 2. For further detail refer to the NI 43-101 Taca Taca Project, November, 2020 available on SEDAR).

This increases the Company’s total Mineral Reserves to over 29 million tonnes of contained copper which is the fifth-largest copper reserve base globally, and substantially increases the geographic diversification of the Company’s copper reserves.

Table 1: Mineral Resource statement as at October 2020, using a 0.13% Cueq cut-off grade

Classification	Volume (Mbcm)	Tonnes (M/t)	Density (t/m3)	Cu grade (%)	Mo grade (%)	Au grade (g/t)	Cu metal (kt)	Mo metal (kt)	Au metal (koz)
Measured	157.7	421.5	2.67	0.60	0.016	0.14	2,542.8	67.02	1,852.6
Indicated	671.6	1,781.8	2.65	0.39	0.011	0.07	6,908.0	197.52	4,199.5
Measured & Indicated	829.3	2,203.3	2.66	0.43	0.012	0.09	9,450.7	264.54	6,052.1
Inferred	269.4	716.9	2.66	0.31	0.009	0.05	2,206.0	65.15	1,182.7

^{Note: The copper equivalent cut-off (“Cueq”) grade accounts for a $3.00/lb copper price, a $1,200/oz gold price, and a $12.00/lb molybdenum price. Inventory and classification are guided by the design ultimate pit. The stated Mineral Resource includes the Mineral Reserve.}

Table
2
:
Mineral
Reserve statement as at October 2020

Classification	Tonnes (M/t)	Cu grade (%)	Mo grade (%)	Au grade (g/t)	Cu metal (kt)	Mo metal (kt)	Au metal (koz)
Proven	408.3	0.59	0.016	0.13	2,401.6	63.3	1,749.8
Probable	1,350.2	0.39	0.011	0.08	5,333.1	150.2	3,336.9
Proven & Probable	1,758.5	0.44	0.012	0.09	7,734.7	213.5	5,086.7

^{Note: The estimated Mineral Reserve was determined using metal prices of $3.00/lb for copper, $12.00/lb for molybdenum, and $1,200/oz for gold. The actual marginal cut-off grade for the Mineral Reserve varies according to the copper recovery assigned to various mineralogical groupings. However, the overall average marginal copper cut-off grade is in the order of 0.13% Cueq_.}

The Report also provides an update on permitting and approvals, engineering progress, detailed production planning, development designs, technical analyses, cost estimates and economic analysis. Work will continue to advance the Taca Taca project and to further refine and optimize the plan. In particular, First Quantum intends to evaluate sources of energy for the project which are more environmentally friendly, including potentially 100% renewables or a combination of renewables and natural gas, and to optimize the energy intensity of the project. The impact of the current carbon tax regime in Argentina is currently not material to the project economics; First Quantum will have full regard for the projects decarbonisation, environmental and social impact prior to the development of Taca Taca.

Qualified Persons

The Taca Taca Technical Report was prepared under the direction and supervision of the following First Quantum personnel who are Qualified Persons for the purposes of NI 43-101: David Gray (QP) BSc (Geology), MAusIMM, FAIG, Group Mine and Resource Geologist, FQM (Australia) Pty Ltd, Michael Lawlor (QP) BEng Hons (Mining), MEngSc, FAusIMM, Consultant Mining Engineer, FQM (Australia) Pty Ltd, Andrew Briggs (QP) BSc (Eng), ARSM, FSAIMM, Group Consultant Metallurgist, FQM (Australia) Pty Ltd.

The scientific and technical information regarding the Taca Taca Mineral Resource and Mineral Reserve estimates set out in this news release has been reviewed and approved by John Gregory (QP) BSc (Eng) Hons, ARSM, CEng, MIMMM, MAusIMM, Group Consultant – Mining, FQM (Australia) Pty Ltd, who is a Qualified Person as defined by NI 43-101.

For further information visit our website at www.first-quantum.com

North American contact: Lisa Doddridge, Director, Investor Relations
Tel: (416) 361-3400 Toll free: 1 (888) 688-6577
United Kingdom contact: Clive Newall, President
E-Mail: [email protected]

CAUTIONARY STATEMENT ON FORWARD-LOOKING INFORMATION

Certain statements and information herein, including all statements that are not historical facts, contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. The forward-looking statements include estimates, forecasts and statements as to the Company’s expectations of production, Mineral Resources and Mineral Reserves at Taca Taca, and the development of Taca Taca (including the timing, cost and details thereof) and are subject to, among other things, the impact of ore grades on future production; the potential of production disruptions; potential production, operational, labour or marketing disruptions as a result of the COVID-19 global pandemic; capital expenditure and mine production costs; a decision to pursue the development of Taca Taca; the outcome of mine permitting, other required permitting; the outcome of legal proceedings which involve the Company; information with respect to the future price of copper, gold, silver, nickel, zinc, pyrite, cobalt, iron and sulphuric acid; estimated Mineral Reserves and Mineral Resources; First Quantum’s exploration and development program; estimated future expenses; exploration and development capital requirements; and the Argentinian fiscal and regulatory regime. Often, but not always, forward-looking statements or information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate” or “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

With respect to forward-looking statements and information contained herein, the Company has made numerous assumptions including among other things, assumptions about continuing production at all operating facilities, the price of copper, gold, silver, nickel, zinc, pyrite, cobalt, iron and sulphuric acid, anticipated costs and expenditures and the ability to achieve the Company’s goals. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. These factors include, but are not limited to, future production volumes and costs, the temporary or permanent closure of uneconomic operations, costs for inputs such as oil, power and sulphur, political stability in jurisdictions in which the Company operates, adverse weather conditions that impact the Company’s operations, labour disruptions, potential social and environmental challenges (including the impact of climate change), power supply, mechanical failures, water supply, procurement and delivery of parts and supplies to the operations, the production of off-spec material and events generally impacting global economic, political and social stability.

See the Company’s Annual Information Form dated March 30, 2020 for additional information on risks, uncertainties and other factors relating to the forward-looking statements and information. Although the Company has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in the forward-looking statements or information, there may be other factors that cause actual results, performances, achievements or events not to be anticipated, estimated or intended. Also, many of these factors are beyond First Quantum’s control. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company undertakes no obligation to reissue or update forward-looking statements or information as a result of new information or events after the date hereof except as may be required by law. All forward-looking statements and information made herein are qualified by this cautionary statement. 

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) — Fosterville South Exploration Ltd. (TSX-V:FSX) is pleased to announce today that, due to strong demand, Leviathan Gold Finance Ltd. (the “Company”) has agreed with Clarus Securities Inc. (“Clarus” or the “Agent”) to further increase the size of its previously announced C$9,990,000 private placement offering. Pursuant to the upsized deal terms, Clarus has agreed to sell up to 25,980,000 subscription receipts (the “Subscription Receipts”) of the Company at a price of $0.50 per Subscription Receipt to raise gross proceeds of up to $12,990,000.

The net proceeds of the Offering will be used by the Company to fund the purchase price for the Avoca and Timor projects and for general working capital.

The securities being offered have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This release does not constitute an offer for sale of securities in the United States.

Closing of the Offering is expected to be on or about December 8, 2020 and is subject to regulatory approval including that of the TSX Venture Exchange.

About Fosterville South Exploration Ltd.

Fosterville South has two large, 100% owned, high-grade epizonal gold projects called the Lauriston and Golden Mountain Projects, a large group of tenement applications called the Providence Project and a large group of recently consolidated tenement applications called the Walhalla Belt Project, all in the state of Victoria, Australia. The Fosterville South land packaged, assembled over a multi-year period, notably includes a 600 sq. km property immediately to the south of and within the same geological framework that hosts Kirkland Lake Gold’s Fosterville tenements. Additionally, Fosterville South has gold-focused projects called the Moormbool, Timor and Avoca Projects, which are also located in the state of Victoria, Australia.

Six of Fosterville South’s properties (Lauriston, Providence, Golden Mountain, Timor, Avoca and Walhalla Belt) have had historical gold production from hard rock sources despite limited modern exploration and drilling.

On behalf of Fosterville South
Bryan Slusarchuk
Chief Executive Officer and Director

Adam Ross, Investor Relations
Direct : (604) 229-9445
Toll Free: 1(833) 923-3334
Email: [email protected]

Forward-Looking Statements

Information set forth in this news release contains
forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs,
intentions
and expectations. They are not
guarantees
of future performance. Fosterville South ca
utions that all
forward looking
statements are inherently uncertain and that actual performance may be affected by many material factors, many of which are beyond their respective control. Such factors include, among other things: risks and uncertainties r
elating to Fosterville South’s
and the Company’s limited operating histories, the
completion of the financing and the need to comply with regulations.  Accordingly,
actual
and future events, conditions and results may differ materially from the estimates,
beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Fosterville South does not undertake to publicly update or revise forward-looking information.

Neither


TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Springfield, MA, Nov. 30, 2020 (GLOBE NEWSWIRE) — Merriam-Webster, the dictionary publisher helping millions of people understand and use language better, has announced its Word of the Year for 2020: pandemic. While the COVID-19 pandemic that has defined 2020 in many ways might make the word seem like a natural choice, the selection is entirely data driven: pandemic was looked up at Merriam-Webster.com in 2020 with remarkable frequency throughout the entire year and in numbers that far exceeded 2019 lookups. In this exceptional year the data was exceptionally clear: the story of the year is the word of the year. Other words also stood out in the dictionary’s 2020 data, and they too shed light on the experiences and ideas that shaped the year.

Lookups of pandemic first spiked on February 3rd, when the first COVID-19 patient in the U.S. was released from the hospital, but close inspection of the dictionary data shows that searches for the word began to tick up consistently starting on January 20th, the date of the first positive case in the U.S. That initial February spike in lookups didn’t fall off—it grew, with dictionary users looking up pandemic an average of 4,000% more in early March than they had been a year previous. The World Health Organization’s March 11th declaration “that COVID-19 can be characterized as a pandemic” pushed lookups into the ether: that day pandemic saw the single largest spike in dictionary traffic in 2020, increasing 115,806% over its 2019 lookups. The word remained high for the remainder of the year.

 “Pandemic is the word that has connected the worldwide medical emergency with the political response and with our personal experience of it all,” says Peter Sokolowski, Editor at Large for Merriam-Webster. “Words that might be part of our general vocabulary send us to the dictionary when they suddenly seem technical, medical, or legal. The word pandemic, though familiar, came into the news this year with an urgent specificity.” 

Gallery: Get more detail on all the 2020 Words of the Year

Other top lookups include malarkey, an old-fashioned word that’s a favorite of President-elect Joe Biden, and one he used several times during the presidential debate in October. The word is defined as “insincere or foolish talk.”

Entertainment and sports also inspired people to turn to the dictionary. The word kraken saw a large spike in lookups when Seattle’s brand-new National Hockey League franchise chose the word as its team name. Nomenclature was also behind searches for antebellum. In June, an award-winning musical trio announced a name change: “Lady Antebellum” would now officially be called “Lady A”; and in September a horror movie using the word as its title was released.

The dictionary’s data also opened a window onto the thoughts of people processing the loss of some prominent and beloved Americans. Mamba rose high in the lookups when basketball great Kobe Bryant, whose nickname was Black Mamba, died in January, and searches for the word icon climbed in reaction to the deaths of both Representative John Lewis in July and Supreme Court Justice Ruth Bader Ginsburg in September.

Podcast: Listen to Merriam-Webster editors discuss the Word of the Year

“The words that rise to prominence when we examine our data at the year’s end always say something about our collective experience. In this case, the Word of the Year is one that has truly touched us all. Pandemic is not only an important medical term; it’s likely that this period of time will be forever known by this word,” says Sokolowski.

Attachment

• word-of-the-year-2020-pandemic_PR.jpg

Meghan Lunghi
Merriam-Webster Inc.
4137343134 x8152
[email protected]